Market Overview

UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name

Share:
Related LLY
UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Sales Decline
Earnings Scheduled For January 30, 2015
Viekira Pak View Falls Short (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated an Underperform rating on Eli Lilly & Co. (NYSE: LLY), and slightly raised the price target from $43.00 to $44.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Eli Lilly & Co. closed on Tuesday at $56.74.

Latest Ratings for LLY

DateFirmActionFromTo
Jan 2015BarclaysMaintainsEqual-weight
Jan 2015Goldman SachsUpgradesSellNeutral
Jan 2015Bank of AmericaDowngradesBuyNeutral

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Around the Web, We're Loving...

Get Benzinga's Newsletters